An In-Depth Analysis of Surufatinib (DB15106): A Novel Angio-Immuno Kinase Inhibitor for Neuroendocrine Tumors

Executive Summary

Surufatinib is a novel, orally administered small-molecule drug developed by HUTCHMED for the treatment of solid tumors. It is distinguished by a unique dual mechanism of action as an "angio-immuno" kinase inhibitor, concurrently targeting pathways involved in tumor angiogenesis and the immune-suppressive tumor microenvironment. Specifically, it potently inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and fibroblast growth factor receptor 1 (FGFR1) to block the formation of new blood vessels, while also inhibiting colony-stimulating factor-1 receptor (CSF-1R) to modulate the activity of tumor-promoting macrophages.

The clinical value of surufatinib has been robustly demonstrated in two pivotal, randomized, placebo-controlled Phase III trials conducted in China. The SANET-ep trial showed that surufatinib significantly improved median progression-free survival (PFS) to 9.2 months versus 3.8 months for placebo in patients with advanced extra-pancreatic neuroendocrine tumors (epNETs). Similarly, the SANET-p trial demonstrated a median PFS of 10.9 months versus 3.7 months for placebo in patients with advanced pancreatic neuroendocrine tumors (pNETs). These compelling results, which led to both trials being stopped early for efficacy, formed the basis for surufatinib's approval in China under the brand name Sulanda®, where it is now an important treatment option for patients with NETs.

In stark contrast to its success in China, surufatinib has faced significant regulatory setbacks in Western markets. In 2022, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL), declining to approve the drug based on a data package comprising the two Chinese trials and a small U.S. bridging study. The FDA cited the need for a multi-regional clinical trial (MRCT) that is more representative of the U.S. patient population and medical practice. Shortly thereafter, HUTCHMED withdrew its Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) after receiving feedback that raised similar concerns about the applicability of the single-country data and compliance with Good Clinical Practice.

The story of surufatinib is therefore one of a drug with proven clinical efficacy but a challenging global regulatory journey. It serves as a critical case study in the evolving landscape of global drug development, highlighting a paradigm shift where data generated exclusively in China, even when scientifically robust, is no longer considered sufficient for approval in the U.S. and Europe without a comprehensive MRCT. The future of surufatinib outside of China is contingent on HUTCHMED's ability to navigate these heightened regulatory expectations, while its development continues in combination therapies for other aggressive cancers.

I. Drug Profile and Chemical Characteristics

This section establishes the fundamental identity of surufatinib, providing the necessary chemical, physical, and commercial context for the compound.

Nomenclature and Identifiers

Surufatinib (DrugBank ID: DB15106) is a small molecule inhibitor of multiple receptor tyrosine kinases [User Query]. The compound was previously known in literature and early development as sulfatinib and is also identified by its development code, HMPL-012.[1] Its Chemical Abstracts Service (CAS) Registry Number is 1308672-74-3.[3] This consistent nomenclature is critical for accurately tracking the drug's development and research history across various scientific and regulatory documents.

Chemical Structure and Physicochemical Properties

Surufatinib's chemical identity is well-defined. Its formal International Union of Pure and Applied Chemistry (IUPAC) name is N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.[3] Physically, it is described as an off-white solid.[3] The molecular formula is

C24​H28​N6​O3​S, corresponding to a molecular weight of 480.59 g/mol.[3] The consistency of these foundational chemical data points across multiple independent chemical suppliers and scientific databases provides a high degree of confidence in the compound's identity, which is the bedrock upon which all reliable preclinical and clinical investigations are built.[3]

Formulation, Solubility, and Stability

For clinical use, surufatinib is administered orally in the form of capsules.[6] Its solubility profile is characteristic of many small molecule kinase inhibitors, showing good solubility in organic solvents like dimethyl sulfoxide (DMSO) at 10 mg/ml and dimethylformamide (DMF) at 30 mg/ml, but poor solubility in ethanol (1 mg/ml) and aqueous solutions like phosphate-buffered saline (PBS) at pH 7.2 (0.12 mg/ml).[4] This solubility profile dictates the requirements for its formulation to ensure adequate oral bioavailability. The compound demonstrates good chemical stability, with a shelf life of at least four years when stored at -20°C.[4]

Developer and Commercial Information

Surufatinib was discovered and developed by HUTCHMED (China) Limited, formerly known as Hutchison China MediTech (Chi-Med).[6] HUTCHMED retains all worldwide rights to the drug.[9] In China, where it has received regulatory approval, surufatinib is marketed under the commercial brand name

Sulanda®.[5] For its European regulatory submission, the proposed trade name was

Sevsury, though this application was ultimately withdrawn.[13]

Table 1: Chemical and Physical Properties of Surufatinib

Property	Value	Source(s)
Common Name	Surufatinib	[User Query]
Synonyms	Sulfatinib, HMPL-012	1
DrugBank ID	DB15106	[User Query]
CAS Number	1308672-74-3	1
Type	Small Molecule	[User Query]
IUPAC Name	N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide	3
Molecular Formula	C24​H28​N6​O3​S	3
Molecular Weight	480.59 g/mol	3
Developer	HUTCHMED (China) Limited	6
Brand Name (China)	Sulanda®	5
Proposed Brand Name (EU)	Sevsury	13

II. Mechanism of Action and Pharmacological Profile

Surufatinib is characterized by a unique and sophisticated mechanism of action that targets two distinct but complementary pillars of cancer progression: tumor angiogenesis and immune evasion. This has led to its classification as a novel "angio-immuno" kinase inhibitor.[2]

Dual-Target Mechanism of Action

Inhibition of Angiogenesis

The "angio" component of surufatinib's activity stems from its potent inhibition of key receptor tyrosine kinases that drive angiogenesis—the process by which tumors form new blood vessels to secure oxygen and nutrients for growth and metastasis.[2] Surufatinib targets:

• Vascular Endothelial Growth Factor Receptors (VEGFR) 1, 2, and 3: These are central regulators of vasculogenesis and angiogenesis.
• Fibroblast Growth Factor Receptor 1 (FGFR1): This receptor is also involved in cell growth and neovascularization.

The potency of this inhibition is demonstrated by its low half-maximal inhibitory concentrations (IC50​), with values of 2 nM for VEGFR1, 24 nM for VEGFR2, 1 nM for VEGFR3, and 15 nM for FGFR1.[4] By blocking these pathways, surufatinib effectively aims to cut off the tumor's blood supply, thereby inhibiting its growth and spread.[6]

Modulation of the Tumor Microenvironment

The "immuno" component of surufatinib's mechanism targets the tumor's ability to evade the host immune system. This is achieved through the inhibition of:

• Colony-Stimulating Factor-1 Receptor (CSF-1R): Surufatinib potently inhibits CSF-1R with an IC50​ of 4 nM.[4]

The CSF-1/CSF-1R signaling axis is critical for the recruitment, differentiation, and survival of macrophages.[2] Within the tumor microenvironment, this pathway promotes the accumulation of tumor-associated macrophages (TAMs), a population of immune cells that are typically polarized to support tumor growth, promote angiogenesis, facilitate metastasis, and suppress the anti-tumor activity of other immune cells, such as T-cells.[2] By inhibiting CSF-1R, surufatinib is designed to reduce the population of these pro-tumorigenic TAMs, thereby remodeling the tumor microenvironment to be less immunosuppressive and potentially more susceptible to immune-mediated destruction.[2]

This dual mechanism is strategically synergistic. It is well-established that resistance to anti-angiogenic therapies can arise through tumor adaptation, where hypoxia induced by VEGFR inhibition can trigger the recruitment of pro-angiogenic immune cells, including TAMs, which then restore blood vessel growth.[2] By simultaneously targeting both VEGFR/FGFR1 and CSF-1R, surufatinib delivers a "one-two punch": it directly attacks the tumor's vascular supply while also preemptively blocking a key immune-mediated escape mechanism. This sophisticated design provides a strong rationale for its potential synergy with other immunotherapies like PD-1 checkpoint inhibitors, as it may help create a more "inflamed" tumor microenvironment that is primed for an effective anti-tumor immune response.[15]

Furthermore, surufatinib exhibits high selectivity. In a broad kinase screen, it was found to be selective for its intended targets over a panel of 278 other kinases, suggesting a focused mechanism with a lower potential for off-target toxicities.[4]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic (PK) profile of surufatinib has been characterized in both preclinical models and human studies, supporting its clinical dosing regimen.

• Absorption and Distribution: Following oral administration, surufatinib is absorbed with a median time to reach maximum plasma concentration (Tmax​) of approximately 4 hours in humans.[18] The parent, or unchanged, drug is the primary radioactive component detected in plasma, indicating that it is the main active entity circulating in the bloodstream.[18]
• Metabolism and Excretion: Surufatinib undergoes extensive metabolism, as the unchanged drug constitutes only a minor fraction of the components found in excreta. However, no single circulating metabolite was found to account for more than 10% of the total radioactivity in plasma, suggesting there are no disproportionately major active metabolites that would complicate its pharmacological profile.[18] The elimination of surufatinib and its metabolites is nearly complete, with over 90% of an administered dose recovered. The primary route of elimination is through fecal excretion (approximately 87% of the dose), with a minor contribution from renal excretion in the urine (approximately 5%). This pattern strongly indicates that biliary excretion is the main pathway for clearance from the body.[18]
• Half-Life and Dosing: The elimination half-life (t1/2​) of surufatinib in humans is approximately 23.3 hours, which supports a convenient once-daily dosing schedule.[6] Clinical pharmacology studies established that drug exposure did not increase when the dose was raised from 300 mg to 350 mg once daily, indicating saturation of absorption or clearance pathways at this level. This finding, along with safety and preliminary efficacy data, led to the selection of 300 mg once daily as the Recommended Phase 2 Dose (RP2D) and the dose used in pivotal trials.[2]
• Population Consistency: A critical finding from the drug's development program was that pharmacokinetic analyses from a U.S. bridging study demonstrated that drug exposure in U.S. patients was comparable to that observed in the Chinese patient populations from the pivotal SANET trials.[2] This consistency was a key piece of evidence intended to support the applicability of the Chinese trial data to a Western population.

Pharmacodynamics

Pharmacodynamic studies have confirmed that surufatinib engages its intended targets in patients. Treatment has been shown to cause measurable changes in circulating biomarkers consistent with its mechanism of action, including increases in plasma VEGF-A and FGF23, and decreases in soluble VEGFR-2 (sVEGFR-2).[2] These biomarker modulations serve as in-vivo proof of target engagement and confirm that the drug is exerting its expected biological effects.

Table 2: Key Pharmacokinetic Parameters of Surufatinib in Humans

PK Parameter	Value	Source(s)
Route of Administration	Oral	6
Recommended Dose	300 mg once daily (QD)	2
Time to Max Concentration (Tmax​)	~4 hours	18
Elimination Half-life (t1/2​)	~23.3 hours	18
Primary Route of Excretion	Fecal (~87%)	18
Major Circulating Moiety	Parent Drug	18

III. Clinical Efficacy in Advanced Neuroendocrine Tumors (NETs)

The clinical efficacy of surufatinib in its primary indication of advanced neuroendocrine tumors (NETs) is defined by two large, pivotal Phase III trials conducted in China—SANET-ep and SANET-p—and supported by a U.S. bridging study. The outcomes of these trials established surufatinib as a highly active agent in this disease.

The SANET-ep Trial (NCT02588170): Extra-Pancreatic NETs

The SANET-ep study was a randomized, double-blind, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of surufatinib in patients with advanced, progressive, well-differentiated (Grade 1 or 2) extra-pancreatic neuroendocrine tumors (epNETs).[20] The trial enrolled 198 patients in China who were randomized in a 2:1 ratio to receive either oral surufatinib 300 mg once daily (n=129) or a matching placebo (n=69).[20]

In a testament to the drug's significant activity, the trial was stopped early in June 2019 at a pre-planned interim analysis after the Independent Data Monitoring Committee (IDMC) concluded that it had met its primary endpoint with overwhelming efficacy.[20]

• Primary Efficacy Outcome: The primary endpoint was investigator-assessed progression-free survival (PFS). The results were highly statistically significant and clinically meaningful:
• The median PFS for patients in the surufatinib arm was 9.2 months.
• The median PFS for patients in the placebo arm was 3.8 months.
• This translated to a 67% reduction in the risk of disease progression or death, with a Hazard Ratio (HR) of 0.334 (95% Confidence Interval [CI], 0.223–0.499; p<0.0001).[11]
• Secondary Efficacy Outcomes: Key secondary endpoints further supported the primary finding:
• The Objective Response Rate (ORR), representing tumor shrinkage, was 10.3% in the surufatinib group compared to 0% in the placebo group.[23]
• The Disease Control Rate (DCR), which includes responses and stable disease, was 86.5% for surufatinib versus 65.7% for placebo.[23]
• Health-Related Quality of Life (HRQoL): A post-hoc analysis of patient-reported outcomes showed that despite a higher incidence of diarrhea, surufatinib therapy was associated with the maintenance of overall HRQoL. Notably, the time until definite deterioration was significantly longer for the domains of dyspnea and social function in the surufatinib arm, indicating a preservation of key aspects of quality of life during treatment.[24]

The SANET-p Trial (NCT02589821): Pancreatic NETs

Running in parallel to SANET-ep, the SANET-p study was a similarly designed randomized, double-blind, placebo-controlled Phase III trial focused on patients with advanced, progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs).[25] The trial randomized 172 patients in China (2:1) to receive surufatinib 300 mg QD (n=113) or placebo (n=59).[25]

Like its counterpart, the SANET-p trial was also stopped early (in January 2020) on the recommendation of its IDMC due to compelling evidence of efficacy at a planned interim analysis.[25]

• Primary Efficacy Outcome: The study met its primary endpoint of investigator-assessed PFS with high statistical significance:
• The median PFS for patients treated with surufatinib was 10.9 months.
• The median PFS for patients receiving placebo was 3.7 months.
• This represented a 51% reduction in the risk of disease progression or death, with an HR of 0.491 (95% CI, 0.32–0.76; p=0.0011).[9]
• Secondary Efficacy Outcomes: The benefit of surufatinib was consistent across secondary measures:
• The ORR was substantially higher in the surufatinib group at 19.2%, compared to just 1.9% for placebo.[22]
• The DCR was 80.8% with surufatinib versus 66.0% with placebo.[22]
• The primary efficacy finding was corroborated by a Blinded Independent Image Review Committee (BIIRC), which found an even more pronounced median PFS benefit of 13.9 months for surufatinib versus 4.6 months for placebo (HR 0.339).[22]

U.S. Bridging Study (NCT02549937): Translating Efficacy to a Western Population

To support a regulatory submission in the United States, HUTCHMED conducted a dose-escalation and expansion study in U.S. patients. The primary goal was to "bridge" the data from the Chinese SANET trials by confirming the safety, PK, and preliminary efficacy of the 300 mg QD dose in a Western population.[19]

The study enrolled a cohort of 32 patients with heavily pre-treated, progressive NETs (16 pNET, 16 epNET). This was a challenging population to treat, with a median of three prior lines of therapy, and all patients had previously received the standard-of-care targeted agents everolimus and/or sunitinib.[19]

Despite the advanced nature of the disease in this cohort, surufatinib demonstrated promising anti-tumor activity:

• The observed median PFS was 11.5 months for patients with epNETs and 15.18 months for patients with pNETs.[28]
• The ORR was 6.3% in the epNET cohort and 18.8% in the pNET cohort.[28]
• The DCR was high across the board at 90.6%.[28]

The robust efficacy demonstrated in the large, randomized SANET trials is undeniable. Both studies met the highest standard of clinical evidence, with IDMCs independently recommending early termination due to the clear benefit of surufatinib over placebo. The magnitude of PFS improvement—5.4 months in epNETs and 7.2 months in pNETs—is highly clinically meaningful for patients with advanced cancer. Furthermore, the U.S. bridging study, though small, suggested that the drug was at least as effective, and perhaps even more so, in a Western patient population that had already exhausted standard therapies. This strong and consistent evidence base across three distinct trials created a significant point of tension and surprise when Western regulatory agencies later rejected the drug, shifting the narrative from one of clinical success to one of regulatory strategy.

Table 3: Pivotal Phase III Trial Efficacy Results (SANET-p & SANET-ep)

Endpoint	SANET-ep (Extra-Pancreatic NETs)	SANET-p (Pancreatic NETs)	Source(s)
	Surufatinib (n=129)	Placebo (n=69)	Surufatinib (n=113)
Median PFS (months)	9.2	3.8	10.9
Hazard Ratio (95% CI)	0.334 (0.223–0.499)	0.491 (0.32–0.76)	22
p-value	<0.0001	0.0011	22
Objective Response Rate (ORR)	10.3%	0%	19.2%
Disease Control Rate (DCR)	86.5%	65.7%	80.8%

IV. Safety, Tolerability, and Risk Management

The safety profile of surufatinib has been extensively characterized through its clinical trial program, with the most robust data derived from a pooled analysis of the two pivotal SANET trials. The observed adverse events are largely consistent with the known class effects of potent VEGFR inhibitors and were deemed manageable.

Profile of Treatment-Emergent Adverse Events (TEAEs)

A pooled analysis of the SANET-ep and SANET-p trials, encompassing 263 patients treated with surufatinib and 133 with placebo, provides a comprehensive overview of the drug's safety.[29]

• Most Common Any-Grade TEAEs: The most frequently reported adverse events of any grade in patients receiving surufatinib were proteinuria (68.8%), hypertension (68.4%), diarrhea (49.0%), increased blood thyroid-stimulating hormone (indicative of hypothyroidism, 42.6%), and increased blood bilirubin (37.6%).[29] These events occurred at substantially higher rates than in the placebo group.
• Most Common Severe (Grade ≥3) TEAEs: The most common clinically significant adverse events (Grade 3 or higher) were hypertension (38.8% vs. 13.5% for placebo) and proteinuria (14.8% vs. 0.8% for placebo). Hypertriglyceridemia was also noted (5.3% vs. 0%).[29] The safety profile observed in the U.S. bridging study was consistent with these findings, with hypertension, diarrhea, and proteinuria being the most common Grade ≥3 events.[28]

The safety profile is a direct reflection of the drug's mechanism of action. Hypertension and proteinuria are well-established class effects associated with potent inhibition of the VEGFR pathway. Their high incidence with surufatinib is therefore not unexpected and falls within the spectrum of toxicities oncologists are accustomed to managing with this class of drugs. This predictability was a key factor in the assessment that the drug's risk-benefit profile was favorable, an assessment underscored by regulatory bodies, which explicitly stated that their non-approval decisions were not related to safety issues.[30]

Table 4: Common and Grade ≥3 Adverse Events from Pooled SANET Analysis

Adverse Event	Surufatinib (Any Grade %)	Placebo (Any Grade %)	Surufatinib (Grade ≥3 %)	Placebo (Grade ≥3 %)
Proteinuria	68.8	54.9	14.8	0.8
Hypertension	68.4	27.1	38.8	13.5
Diarrhea	49.0	22.6	2.3	0.8
Blood TSH Increased	42.6	9.8	0	0
Blood Bilirubin Increased	37.6	19.5	1.9	0
Hypertriglyceridemia	35.7	12.0	5.3	0
Source: 29

Management of Key Toxicities

Although adverse events were frequent, they were generally manageable with proactive monitoring and intervention. The median time to onset for both hypertension and proteinuria was less than one month, highlighting the need for early and regular monitoring of blood pressure and urinalysis upon treatment initiation.[29]

Dose modification was a key strategy for managing toxicity. In the pooled analysis, TEAEs led to dose reductions in 43.0% of patients and dose interruptions in 47.1%.[29] A real-world study similarly found that approximately one-third of patients required a dose reduction from the standard 300 mg daily dose to 250 mg or 200 mg, which in most cases successfully mitigated the adverse events.[23] Despite the high frequency of dose modifications, the majority of patients (83.3%) were able to continue treatment without permanent discontinuation due to AEs, indicating that these toxicities, while common, did not typically necessitate stopping this effective therapy.[29]

Contraindications and Drug-Drug Interactions

Based on its mechanism of action and observed toxicities, surufatinib has several contraindications and potential drug-drug interactions (DDIs).

• Contraindications: The use of surufatinib is contraindicated in patients with a history of severe or uncontrolled cardiovascular diseases (including uncontrolled hypertension) and those with significant bleeding disorders.[6] Clinical trial protocols systematically excluded patients with these conditions.[33]
• Drug-Drug Interactions: Surufatinib is a substrate of the cytochrome P450 enzyme CYP3A4, which is a major pathway for drug metabolism in the liver.[6] This creates potential for significant DDIs:
• CYP3A4 Inhibitors: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) can impair the metabolism of surufatinib, leading to increased plasma concentrations and a higher risk of toxicity. This combination should generally be avoided or managed with extreme caution and potential dose reduction of surufatinib.[6]
• CYP3A4 Inducers: Conversely, co-administration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can accelerate the metabolism of surufatinib, leading to decreased plasma concentrations and potentially reduced efficacy. This combination should be avoided.[6]
• QT-Prolonging Agents: Caution is also advised when using surufatinib concurrently with other medications known to prolong the QT interval, due to a potential additive risk of cardiac arrhythmias.[6]

V. Global Regulatory Journey and Market Access

The regulatory history of surufatinib is a tale of two vastly different outcomes, marked by decisive success in China and comprehensive rejection in the West. This divergence provides a critical lens through which to view the current landscape of global pharmaceutical development and regulation.

Success in China: NMPA Approval and Commercialization

Leveraging the compelling, positive results from the domestically conducted SANET-ep and SANET-p trials, HUTCHMED achieved regulatory success in China. The National Medical Products Administration (NMPA) granted two separate approvals for surufatinib, marketed as Sulanda®:

• December 2020: Approval for the treatment of advanced, well-differentiated extra-pancreatic NETs (epNETs), based on the SANET-ep data.[7]
• June 2021: Approval for the treatment of advanced pancreatic NETs (pNETs), based on the SANET-p data.[9]

These approvals represented a major corporate milestone for HUTCHMED, as surufatinib became its first self-discovered oncology drug to reach the market without a development partner.[11] The drug was subsequently included in China's National Reimbursement Drug List (NRDL) in January 2022, ensuring broad patient access within the country.[12]

The U.S. FDA Complete Response Letter (CRL)

HUTCHMED's strategy for U.S. approval was based on an agreement reached with the FDA in a pre-New Drug Application (NDA) meeting in May 2020. The understanding was that the two positive Chinese Phase III studies, supported by data from the U.S. bridging study, could form the basis of an NDA submission.[31] The NDA was subsequently submitted and accepted for review by the FDA in July 2021, with a target action date of April 30, 2022.[15]

However, on May 2, 2022, HUTCHMED announced it had received a Complete Response Letter (CRL) from the FDA, formally rejecting the application in its current form.[30] The reasons cited by the FDA were not related to the drug's safety or efficacy per se, but rather the nature and origin of the evidence package:

1. Requirement for a Multi-Regional Clinical Trial (MRCT): The FDA stated that the data package, derived primarily from a single country (China), was insufficient. The agency determined that a new MRCT, designed to include subjects more representative of the diverse U.S. patient population, would be required to support an approval.[31]
2. Concerns Over Data Applicability: The agency explicitly questioned the applicability of the SANET study data to U.S. patients and contemporary U.S. medical practice.[30] This reflects a concern that differences in intrinsic factors (e.g., genetics, diet) and extrinsic factors (e.g., standards of care, concomitant medications) between the Chinese and U.S. populations could limit the generalizability of the trial results.
3. Pandemic-Related Issues: The CRL also noted that pandemic-related difficulties in scheduling and conducting on-site inspections of clinical and manufacturing facilities in China contributed to the decision.[30]

The European Medicines Agency (EMA) MAA Withdrawal

A similar story unfolded in Europe. HUTCHMED's Marketing Authorization Application (MAA) for surufatinib was validated by the EMA in July 2021.[8] However, on August 1, 2022, the company formally withdrew the application before a final decision was rendered.[13]

The withdrawal was prompted by feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP), which had communicated a provisional opinion that the drug could not be authorized. The concerns raised by the EMA mirrored those of the FDA and were even more detailed:

1. Data Robustness and Study Conduct: The agency cited "important uncertainties regarding the design and conduct of the main studies".[13]
2. Good Clinical Practice (GCP): The EMA explicitly raised concerns about compliance with GCP standards in the trials.[13]
3. Manufacturing Quality: Concerns were also noted regarding the documentation of the drug's manufacturing process.[13]

In its withdrawal letter, HUTCHMED acknowledged that it was unable to satisfactorily address these fundamental concerns within the procedural timelines.[13]

The regulatory rejections of surufatinib in both the U.S. and Europe, despite the existence of a prior agreement with the FDA on the submission package, represent a significant paradigm shift. This case, along with the similar rejection of the PD-1 inhibitor sintilimab, serves as a landmark event signaling a clear tightening of evidentiary standards by Western regulators for drugs developed primarily or exclusively in China. While earlier drugs had gained approval based on China-only data (e.g., zanubrutinib), the bar has now been raised significantly.[40] The surufatinib story is a cautionary tale for the global pharmaceutical industry, demonstrating that the strategy of using single-country data supplemented by a small bridging study is no longer a viable path to approval in the U.S. or EU for most indications. The clear message is that future drug development intended for global markets must incorporate MRCTs from an early stage, a far more complex and costly endeavor.

Table 5: Global Regulatory Submission and Outcome Summary

Regulatory Agency	Action	Date	Outcome / Reason	Source(s)
NMPA (China)	epNET Approval	Dec 2020	Approved based on SANET-ep trial results.	7
	pNET Approval	Jun 2021	Approved based on SANET-p trial results.	9
FDA (U.S.)	NDA Accepted	Jul 2021	PDUFA date set for April 30, 2022.	15
	Complete Response Letter	May 2022	Rejected. Required a multi-regional clinical trial (MRCT); cited concerns over applicability of single-country data to U.S. population and medical practice.	30
EMA (Europe)	MAA Validated	Jul 2021	Formal review commenced.	8
	MAA Withdrawn	Aug 2022	Withdrawn by applicant. EMA had concerns about study design, GCP compliance, and manufacturing. Provisional opinion was that benefits did not outweigh risks.	13

VI. Comparative Analysis and Therapeutic Positioning

To understand the clinical potential of surufatinib, it is essential to position it within the existing therapeutic landscape for advanced NETs by comparing its efficacy against established treatments.

Real-World Evidence vs. Competitors

A retrospective, observational study conducted at the Fudan University Shanghai Cancer Center provides the most direct, albeit non-randomized, comparison of surufatinib against the standard-of-care targeted therapies sunitinib and everolimus in a real-world setting.[41]

• In Pancreatic NETs (pNETs): The study found that surufatinib demonstrated statistically superior efficacy. The median PFS for surufatinib was 8.67 months, compared to 6.40 months for sunitinib (p=0.04) and 5.37 months for everolimus (p=0.05). The ORR was also higher for surufatinib at 17.1%, versus 10.9% for sunitinib and 3.8% for everolimus.[41]
• In Extra-Pancreatic NETs (epNETs): Surufatinib showed a numerical trend towards improved efficacy over everolimus, with a median PFS of 9.47 months versus 6.70 months, though this difference did not reach statistical significance (p=0.15).[41]

Cross-Trial Comparison with Approved Agents

While direct comparisons from randomized trials are lacking, a cross-trial comparison of pivotal study data provides valuable context.

• Sunitinib (Sutent®): Approved for pNETs, sunitinib demonstrated a median PFS of 11.4 months versus 5.5 months for placebo in its pivotal Phase III trial.[42] A subsequent Phase IV post-approval study confirmed this benefit, showing a median PFS of 13.2 months and an ORR of 24.5%.[43]
• Everolimus (Afinitor®): Approved for both pNETs and non-functional GI/lung NETs. In the RADIANT-3 trial for pNETs, everolimus showed a median PFS of 11.0 months versus 4.6 months for placebo.[45] In the RADIANT-4 trial for non-functional epNETs, the median PFS was also 11.0 months versus 3.9 months for placebo.[46]
• Lanreotide (Somatulin® Depot): This somatostatin analog is used for well-differentiated gastroenteropancreatic (GEP)-NETs. In the CLARINET study, which enrolled patients with more indolent, non-functioning tumors (Ki-67 index ≤10%), lanreotide demonstrated a very long median PFS, estimated to be 32.8 months from the long-term open-label extension.[47]

Therapeutic Positioning

The collective data suggests that surufatinib is a highly competitive agent in the treatment of progressive, well-differentiated NETs. Its median PFS of 10.9 months in pNETs from the SANET-p trial is directly comparable to the 11.0-11.4 month PFS demonstrated by everolimus and sunitinib in their respective pivotal trials. The real-world data from China further strengthens this position, suggesting potential superiority.[41] The comparison with lanreotide is less direct, as lanreotide is typically used in patients with less aggressive, slower-growing tumors, leading to longer observed PFS.

The critical question, as noted by experts, is where surufatinib fits into the complex treatment algorithm for NETs.[38] The data from the U.S. bridging study, which showed efficacy in patients who had already failed everolimus and/or sunitinib, suggests that surufatinib has activity in a later-line setting.[28] Its unique CSF-1R inhibitory activity might also position it as a preferred agent for certain patient subgroups or as an ideal partner for combination with immunotherapy.

However, without regulatory approval in the U.S. or Europe, surufatinib's role in the global treatment algorithm remains purely theoretical. Its use is confined to China and ongoing clinical trials, leaving a significant unmet need for additional treatment options for NET patients in Western countries.

VII. Future Directions and Expert Outlook

Despite its regulatory setbacks in the West for neuroendocrine tumors, the development of surufatinib continues, with a strategic focus on leveraging its unique angio-immuno mechanism in other malignancies and in combination therapies.

Ongoing and Planned Clinical Trials

HUTCHMED is actively pursuing the development of surufatinib in several other cancer types, primarily as part of combination regimens designed to exploit potential synergies.

• Pancreatic Ductal Adenocarcinoma (PDAC): A major Phase II/III trial (NCT06361888) is evaluating surufatinib in combination with the PD-1 inhibitor camrelizumab and standard chemotherapy (nab-paclitaxel and gemcitabine) for first-line treatment of metastatic PDAC. This ambitious trial reflects the strong scientific rationale for combining surufatinib's angio-immuno modulation with checkpoint inhibition and chemotherapy, with initial data readouts anticipated in late 2025.[12]
• Biliary Tract Cancers (BTC): A Phase II study (NCT05056116) is investigating surufatinib in combination with the PD-1 inhibitor toripalimab in patients with recurrent BTC.[49]
• Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Phase II trial (NCT05509699) is exploring surufatinib plus an anti-PD-1/L1 antibody as maintenance therapy following initial chemotherapy.[50]
• Hepatocellular Carcinoma (HCC): Surufatinib is also being studied as a single agent in advanced HCC, with patient selection guided by single-cell sequencing of tumor samples (NCT05171439).[51]

This development strategy underscores a clear shift towards combination therapies, where surufatinib's ability to remodel the tumor microenvironment may enhance the efficacy of both immunotherapy and chemotherapy.

The Path Forward for NETs

For the NET indication in the U.S. and Europe, the path forward is narrow and challenging. The FDA has explicitly stated that a new Multi-Regional Clinical Trial (MRCT) is required for approval.[31] Such a trial would need to be designed from the outset to include a diverse, global patient population representative of Western countries. Furthermore, given the availability of effective treatments like everolimus and sunitinib, it would likely need to use an active comparator as its control arm rather than placebo. This represents a substantial financial and operational investment for HUTCHMED, and the company's decision on whether to undertake such a trial will ultimately determine the drug's fate in Western markets.[40]

Concluding Expert Assessment

Surufatinib is a well-characterized small-molecule inhibitor with a rational and sophisticated dual mechanism of action targeting both tumor angiogenesis and immune evasion. Its clinical efficacy in advanced, well-differentiated neuroendocrine tumors is supported by high-quality evidence from two large, randomized, placebo-controlled Phase III trials, which demonstrated clinically meaningful improvements in progression-free survival with a predictable and manageable safety profile.

However, the story of surufatinib serves as a powerful and cautionary case study in the complexities of modern global drug development. Its regulatory failures in the United States and Europe were not a reflection of the drug's intrinsic clinical value, but rather a consequence of an evidence package that, while sufficient for approval in China, was deemed inadequate by Western agencies. These agencies have demonstrated a clear and heightened expectation for multi-regional clinical trial data that is directly applicable to their diverse patient populations and standards of care.

Consequently, the future of surufatinib is bifurcated. In China, it is an established and valuable therapeutic option for patients with NETs. Globally, its potential in this indication remains unrealized, contingent upon the successful completion of a new and costly MRCT. The most promising path forward for surufatinib on the international stage may lie in its ongoing development in combination therapies for other aggressive cancers, provided these new, ambitious trials are designed from their inception to meet the rigorous evidentiary standards of a global regulatory environment.

Works cited

1. Sulfatinib CAS:1308672-74-3 - Ruixibiotech, accessed August 7, 2025, https://www.ruixibiotech.com/pts/sulfatinib
2. Current treatments and future potential of surufatinib in ..., accessed August 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8411625/
3. Sulfatinib | CAS 1308672-74-3 | Sun-shinechem, accessed August 7, 2025, https://www.sun-shinechem.com/Details/Sulfatinib/3552/1308672-74-3.html
4. Sulfatinib (HMPL-012, CAS Number: 1308672-74-3) | Cayman ..., accessed August 7, 2025, https://www.caymanchem.com/product/34206/sulfatinib
5. Surufatinib - Wikipedia, accessed August 7, 2025, https://en.wikipedia.org/wiki/Surufatinib
6. What is Surufatinib used for? - Patsnap Synapse, accessed August 7, 2025, https://synapse.patsnap.com/article/what-is-surufatinib-used-for
7. Surufatinib: First Approval - PubMed, accessed August 7, 2025, https://pubmed.ncbi.nlm.nih.gov/33788183/
8. HUTCHMED's Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency, accessed August 7, 2025, https://www.hutch-med.com/maa-for-surufatinib-submitted-and-validated-by-ema/
9. HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors - GlobeNewswire, accessed August 7, 2025, https://www.globenewswire.com/news-release/2021/06/18/2249756/0/en/HUTCHMED-Announces-NMPA-Approval-of-Surufatinib-Sulanda-in-China-for-Advanced-Pancreatic-Neuroendocrine-Tumors.html
10. Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA's CHMP - HUTCHMED, accessed August 7, 2025, https://www.hutch-med.com/chi-med-plans-to-submit-maa-for-surufatinib/
11. Chi-Med Announces The NMPA Approval Of Surufatinib (Sulanda® In China) For Non-Pancreatic Neuroendocrine Tumors - Clival Database, accessed August 7, 2025, https://clival.com/news/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-non-pancreatic-neuroendocrine-tumors
12. HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui, accessed August 7, 2025, https://www.hutch-med.com/surufatinib-camrelizumab-pdac/
13. Sevsury | European Medicines Agency (EMA), accessed August 7, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/sevsury
14. Withdrawal Assessment report - EMA, accessed August 7, 2025, https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sevsury_en.pdf
15. US FDA Accepts Filing of HUTCHMED's NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors, accessed August 7, 2025, https://www.hutch-med.com/fda-accepts-surufatinib-nda-for-net/
16. Updated results from a multicenter, single-arm phase II study of surufatinib plus sintilimab and IBI310 in patients with high-grade advanced-neuroendocrine neoplasm (HG-NEN). | Journal of Clinical Oncology - ASCO Publications, accessed August 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e16342
17. Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors - HUTCHMED, accessed August 7, 2025, https://www.hutch-med.com/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-epnet/
18. Absorption, Metabolism and Excretion of Surufatinib in Rats and ..., accessed August 7, 2025, https://pubmed.ncbi.nlm.nih.gov/32407271/
19. Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs). - ASCO Publications, accessed August 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.4610
20. The Lancet Oncology: Surufatinib SANET-ep phase 3 study - HUTCHMED, accessed August 7, 2025, https://www.hutch-med.com/the-lancet-oncology-surufatinib-sanet-ep/
21. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study | Request PDF - ResearchGate, accessed August 7, 2025, https://www.researchgate.net/publication/344371038_Surufatinib_in_advanced_extrapancreatic_neuroendocrine_tumours_SANET-ep_a_randomised_double-blind_placebo-controlled_phase_3_study
22. Chi-Med Highlights Surufatinib Phase III Results in ... - HUTCHMED, accessed August 7, 2025, https://www.hutch-med.com/surufatinib-phase-iii-results-at-esmo-2020-and-publications-in-the-lancet-oncology/
23. Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumors: a 102-case retrospective study. - Oxford Academic, accessed August 7, 2025, https://academic.oup.com/oncolo/article-pdf/30/5/oyaf072/63370828/oyaf072.pdf
24. Health-Related Quality-of-Life Results of Surufatinib in Advanced Extrapancreatic NETs (SANET-ep Trial), accessed August 7, 2025, https://www.jons-online.com/special-issues-and-supplements/2020/2020-year-in-review-neuroendocrine-tumors/3421:health-related-quality-of-life-results-of-surufatinib-in-advanced-extrapancreatic-nets-sanet-ep-trial
25. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study - PubMed, accessed August 7, 2025, https://pubmed.ncbi.nlm.nih.gov/32966810/
26. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study | Request PDF - ResearchGate, accessed August 7, 2025, https://www.researchgate.net/publication/344370938_Surufatinib_in_advanced_pancreatic_neuroendocrine_tumours_SANET-p_a_randomised_double-blind_placebo-controlled_phase_3_study
27. Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early - HUTCHMED, accessed August 7, 2025, https://www.hutch-med.com/surufatinib-phase-iii-sanet-p-study-achieved-primary-endpoint/
28. Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs)., accessed August 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4114
29. A pooled analysis of surufatinib safety from phase 3 trials in ... - ASCO, accessed August 7, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT375292
30. FDA Issues Complete Response Letter for Surufatinib in pNETS and epNETS, accessed August 7, 2025, https://www.cancernetwork.com/view/fda-issues-complete-response-letter-for-surufatinib-in-pnets-and-epnets
31. HUTCHMED Receives Complete Response Letter from the US FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors, accessed August 7, 2025, https://www.hutch-med.com/suru-fda-nda/
32. Surufatinib - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 7, 2025, https://synapse.patsnap.com/drug/8d924fb5405644cea2a5490f41b884f7
33. Study Details | Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma | ClinicalTrials.gov, accessed August 7, 2025, https://clinicaltrials.gov/study/NCT06447636
34. Study Details | Surufatinib DDI With a PPI and a CYP3A Inducer | ClinicalTrials.gov, accessed August 7, 2025, https://clinicaltrials.gov/study/NCT04510649
35. Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors, accessed August 7, 2025, https://clinicaltrials.gov/study/NCT02589821
36. HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors - GlobeNewswire, accessed August 7, 2025, https://www.globenewswire.com/news-release/2022/05/02/2433243/0/en/HUTCHMED-Receives-Complete-Response-Letter-from-the-U-S-FDA-for-Surufatinib-for-the-Treatment-of-Advanced-Neuroendocrine-Tumors.html
37. Surufatinib: What is it and is it FDA approved? - Drugs.com, accessed August 7, 2025, https://www.drugs.com/history/surufatinib.html
38. FDA Does Not Approve TKI Surufatinib for Neuroendocrine Tumors - Medscape, accessed August 7, 2025, https://www.medscape.com/viewarticle/973228
39. Hutchmed hit with complete response letter for China-tested cancer drug surufatinib, accessed August 7, 2025, https://firstwordpharma.com/story/5560709
40. FDA's complete response letter may cost HUTCHMED nearly $100m in potential sales, accessed August 7, 2025, https://www.pharmaceutical-technology.com/analyst-comment/fda-complete-response-letter-hutchmed/
41. Performance of surufatinib in treating advanced neuroendocrine neoplasms: Insights from a real-world study. - ASCO Publications, accessed August 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e15124
42. Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib - PubMed Central, accessed August 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7810649/
43. The efficacy and safety of sunitinib in patients with advanced well ..., accessed August 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2017.35.4_suppl.380
44. The Efficacy and Safety of Sunitinib in Patients with Advanced Well-differentiated Pancreatic Neuroendocrine Tumors - NANETS, accessed August 7, 2025, https://nanets.net/abstracts-archive/2016/441-c10-the-efficacy-and-safety-of-sunitinib-in-patients-with-advanced-well-differentiated-pancreatic-neuroendocrine-tumors/file
45. Efficacy and safety of everolimus in patients with advanced low- or ..., accessed August 7, 2025, https://ascopubs.org/doi/10.1200/jco.2013.31.4_suppl.224
46. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature - PMC, accessed August 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4943387/
47. Anti-tumour effects of lanreotide for pancreatic and intestinal ..., accessed August 7, 2025, https://erc.bioscientifica.com/view/journals/erc/23/3/191.xml
48. HUTCHMED Reports 2025 Interim Results, accessed August 7, 2025, https://www.hutch-med.com/2025-half-year-results/
49. Biliary Cancers Unknown Status Phase Trials for Surufatinib (DB15106) | DrugBank Online, accessed August 7, 2025, https://go.drugbank.com/indications/DBCOND0105412/clinical_trials/DB15106?phase=&status=unknown_status
50. Extensive-Stage Small Cell Lung Cancer Unknown Status Phase 2 Trials for Surufatinib (DB15106) - DrugBank, accessed August 7, 2025, https://go.drugbank.com/indications/DBCOND0040175/clinical_trials/DB15106?phase=2&status=unknown_status
51. Surufatinib Unknown Status Phase 2 Trials for Hepatocellular Carcinoma Treatment, accessed August 7, 2025, https://go.drugbank.com/drugs/DB15106/clinical_trials?conditions=DBCOND0030090&phase=2&purpose=treatment&status=unknown_status